GlaxoSmithKline (LON:GSK) Price Target Raised to GBX 1,575
GlaxoSmithKline (LON:GSK) had its target price raised by Deutsche Bank from GBX 1,550 ($20.25) to GBX 1,575 ($20.58) in a report released on Monday morning, Digital Look reports. They currently have a hold rating on the stock.
A number of other analysts have also commented on GSK. UBS Group lowered Telstra from a buy rating to a neutral rating in a report on Monday, July 1st. Credit Suisse Group initiated coverage on Regeneron Pharmaceuticals in a research note on Monday, May 20th. They issued a neutral rating and a $336.00 target price on the stock. Morgan Stanley initiated coverage on in a research note on Monday, June 17th. They issued an equal weight rating and a GBX 215 ($2.81) target price on the stock. Bryan, Garnier & Co cut their target price on GlaxoSmithKline from GBX 1,710 ($22.34) to GBX 1,660 ($21.69) and set a neutral rating on the stock in a research note on Thursday, May 2nd. Finally, Goldman Sachs Group set a $13.00 target price on Ford Motor and gave the stock a buy rating in a research note on Thursday, June 13th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus price target of GBX 1,535.88 ($20.07).
GSK traded down GBX 10.80 ($0.14) during midday trading on Monday, reaching GBX 1,632.40 ($21.33). 7,804,311 shares of the company were exchanged, compared to its average volume of 9,120,000. The company has a debt-to-equity ratio of 942.07, a quick ratio of 0.45 and a current ratio of 0.72. The stock has a fifty day moving average of GBX 1,582.47. The company has a market cap of $81.44 billion and a P/E ratio of 20.79. GlaxoSmithKline has a one year low of GBX 1,408.80 ($18.41) and a one year high of GBX 1,651 ($21.57).
In other news, insider Manvinder Singh Banga acquired 458 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The shares were acquired at an average price of GBX 1,568 ($20.49) per share, for a total transaction of £7,181.44 ($9,383.82). In the last quarter, insiders purchased 482 shares of company stock worth $755,935.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Further Reading: Oversold
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.